Literature DB >> 25665949

Rates of Neoadjuvant Chemotherapy and Oncoplastic Surgery for Breast Cancer Surgery: A French National Survey.

Krishna B Clough1, Victor Acosta-Marín2,3, Claude Nos2, Séverine Alran4, Philippe Rouanet5, Jean-Rémi Garbay6, Sylvia Giard7, Jean-Luc Verhaeghe8, Gilles Houvenaeghel9, Bernard Flipo10, Jacques Dauplat11, Pierre Hervé Dorangeon12, Jean-Marc Classe13, Roman Rouzier14, Pascal Bonnier15.   

Abstract

BACKGROUND: The current retrospective study was intended to obtain up-to-date and comprehensive data on surgical practice for breast cancer throughout France, including neoadjuvant chemotherapy (NAC) and the more recent surgical techniques of oncoplastic surgery (OPS).
METHODS: In June 2011, e-mail surveys were sent to 33 nationally renowned breast cancer surgeons from French public or private hospitals. The questionnaire focused on all the new cases of breast cancer treated in 2010. It included questions regarding surgical practices, with special emphases on NAC and OPS and other surgical characteristics.
RESULTS: The overall response rate for the survey was 72.7 %. The total number of breast cancer cases from the survey was 13,762, which constitutes 26.2 % of the total incidence in 2010. Breast-conserving surgery (BCS) was performed for 71.0 % of the patients, and the results were similar throughout the types of practices. Of these patients, 13.9 % received OPS, either upfront or after NAC. Mastectomy was performed for 29.0 % of the patients, which is consistent with French official numbers. Among all patients, 16.3 % underwent surgery after NAC.
CONCLUSION: To the authors' knowledge, there are no publications of national figures on NAC or OPS rates to date. They are convinced that this study offers real-life surgical care information on a large population and covers France's breast cancer surgical landscape. Mastectomy rates in France remain stable and consistent with those in other European countries. However, additional large-scale retrospective studies are required to confirm these figures and further explore NAC and OPS rates as well as surgical practice characteristics.

Entities:  

Mesh:

Year:  2015        PMID: 25665949     DOI: 10.1245/s10434-015-4378-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  15 in total

1.  Revisiting the modern toolkit to optimize breast conservation surgery.

Authors:  David M Lesniak; Krishna B Clough; Brigid K Killelea
Journal:  Gland Surg       Date:  2020-04

2.  Economic Impact of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in France.

Authors:  Gregory Katz; Olivier Romano; Cyril Foa; Anne-Lise Vataire; Jean-Victor Chantelard; Robert Hervé; Hugues Barletta; Axel Durieux; Jean-Pierre Martin; Rémy Salmon
Journal:  PLoS One       Date:  2015-06-18       Impact factor: 3.240

3.  Axillary Response in Patients Undergoing Neoadjuvant Endocrine Treatment for Node-Positive Breast Cancer: Systematic Literature Review and NCDB Analysis.

Authors:  Arielle Stafford; Austin Williams; Kirsten Edmiston; Costanza Cocilovo; Robert Cohen; Sara Bruce; Kahyun Yoon-Flannery; Lucy De La Cruz
Journal:  Ann Surg Oncol       Date:  2020-09-09       Impact factor: 5.344

4.  Neoadjuvant Chemotherapy Plays an Adverse Role in the Prognosis of Grade 2 Breast Cancer.

Authors:  Xudong Zhu; Jinqi Xue; Xi Gu; Guanglei Chen; Fangning Cao; Huilian Shan; Dan Wang; Xinbo Qiao; Caigang Liu; Yixiao Zhang
Journal:  J Cancer       Date:  2019-09-07       Impact factor: 4.207

5.  Breast conserving surgery versus salvage mastectomy for ipsilateral breast cancer recurrence: a propensity score matching analysis.

Authors:  Damiano Gentile; Andrea Sagona; Erika Barbieri; Lidija Antunovic; Davide Franceschini; Agnese Losurdo; Bethania Fernandes; Corrado Tinterri
Journal:  Updates Surg       Date:  2021-06-28

6.  Quantitative Comparison of Prone and Supine PERCIST Measurements in Breast Cancer.

Authors:  Jennifer G Whisenant; Jason M Williams; Hakmook Kang; Lori R Arlinghaus; Richard G Abramson; Vandana G Abramson; Kareem Fakhoury; A Bapsi Chakravarthy; Thomas E Yankeelov
Journal:  Tomography       Date:  2020-06

Review 7.  Whole genome sequencing of breast cancer.

Authors:  Maria Rossing; Claus Storgaard Sørensen; Bent Ejlertsen; Finn Cilius Nielsen
Journal:  APMIS       Date:  2019-01-28       Impact factor: 3.205

8.  Do early HER2-overexpression breast cancer patients benefit from undergoing neoadjuvant trastuzumab and mastectomy? A meta-analysis.

Authors:  Lin He; Qian Wu; Jing Xiong; Zhumin Su; Biyuan Zhang; Yuhua Song
Journal:  Cancer Manag Res       Date:  2019-08-29       Impact factor: 3.989

Review 9.  Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.

Authors: 
Journal:  Lancet Oncol       Date:  2017-12-11       Impact factor: 41.316

10.  Comparison of Segmentation Methods in Assessing Background Parenchymal Enhancement as a Biomarker for Response to Neoadjuvant Therapy.

Authors:  Alex Anh-Tu Nguyen; Vignesh A Arasu; Fredrik Strand; Wen Li; Natsuko Onishi; Jessica Gibbs; Ella F Jones; Bonnie N Joe; Laura J Esserman; David C Newitt; Nola M Hylton
Journal:  Tomography       Date:  2020-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.